Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

OfficialStocktwitsUser Feb. 18 at 5:03 PM

$IMNN RSI: 42.57, MACD: -0.1033 Vol: 0.18, MA20: 3.35, MA50: 3.60 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

RaKa82 Feb. 18 at 3:41 PM

$IMNN this reminds me of PRAX. About 2 years ago, PRAX had a 15:1 reverse split, which really shrunk the share count to levels similar to IMNN. Then came data, and 2 years later PRAX is sitting at $330/share. I’m not saying same exact thing will play out here or when, but the similarities are striking imo. If data is positive, and an interim readout could be released later this year, this very much has the potential to erupt violently

0 · Reply

ConcernedCitizen23 Feb. 18 at 12:19 PM

$IMNN armistice capital is a $6.5billion hedge fund. We need more investors like this. Pretty good news!

1 · Reply

rrch Feb. 18 at 11:57 AM

$IMNN new 10 percent shareholder reported

0 · Reply

LKDOG Feb. 17 at 9:08 PM

$IMNN They know the value they have. I am happy to wait . All upside

1 · Reply

ConcernedCitizen23 Feb. 17 at 3:57 PM

$IMNN the ceo keeps doing pod casts which is good. Whoever bought the PIPE is holding firm. Would love to know who it was

0 · Reply

LKDOG Feb. 10 at 6:58 PM

$IMNN Decimal should be two places to the right, when adding in DNA based inoculations & Alabama facility 😎

1 · Reply

LKDOG Feb. 10 at 6:44 PM

$IMNN After hrs should be interesting

0 · Reply

LKDOG Feb. 10 at 6:30 PM

$IMNN Adding 😎🤑 Run forest …. Run !!!!

1 · Reply

bomber1 Feb. 10 at 6:30 PM

$IMNN without volumes? fake pump

0 · Reply

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

Dec 30, 2025, 8:30 AM EST - 7 weeks ago

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Dec 29, 2025, 11:10 AM EST - 7 weeks ago

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Nov 13, 2025, 5:31 PM EST - 3 months ago

Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:45 AM EST - 3 months ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 5:11 PM EST - 3 months ago

Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript

Nov 10, 2025, 1:30 PM EST - 3 months ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Nov 10, 2025, 7:30 AM EST - 3 months ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 3 months ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 3 months ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 3 months ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 30, 2025, 8:00 AM EDT - 4 months ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 4 months ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 4 months ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 4 months ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

Oct 14, 2025, 8:20 AM EDT - 4 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Sep 22, 2025, 8:05 AM EDT - 5 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Sep 19, 2025, 8:05 AM EDT - 5 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Aug 28, 2025, 8:05 AM EDT - 6 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 7 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 7 months ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 7 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 7 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 7 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 7 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 8 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 9 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 9 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 9 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 9 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 10 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 10 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 10 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 11 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 1 year ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 1 year ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 1 year ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

OfficialStocktwitsUser Feb. 18 at 5:03 PM

0 · Reply

RaKa82 Feb. 18 at 3:41 PM

0 · Reply

ConcernedCitizen23 Feb. 18 at 12:19 PM

$IMNN armistice capital is a $6.5billion hedge fund. We need more investors like this. Pretty good news!

1 · Reply

rrch Feb. 18 at 11:57 AM

$IMNN new 10 percent shareholder reported

0 · Reply

LKDOG Feb. 17 at 9:08 PM

$IMNN They know the value they have. I am happy to wait . All upside

1 · Reply

ConcernedCitizen23 Feb. 17 at 3:57 PM

$IMNN the ceo keeps doing pod casts which is good. Whoever bought the PIPE is holding firm. Would love to know who it was

0 · Reply

LKDOG Feb. 10 at 6:58 PM

$IMNN Decimal should be two places to the right, when adding in DNA based inoculations & Alabama facility 😎

1 · Reply

LKDOG Feb. 10 at 6:44 PM

$IMNN After hrs should be interesting

0 · Reply

LKDOG Feb. 10 at 6:30 PM

$IMNN Adding 😎🤑 Run forest …. Run !!!!

1 · Reply

bomber1 Feb. 10 at 6:30 PM

$IMNN without volumes? fake pump

0 · Reply

ConcernedCitizen23 Feb. 10 at 6:14 PM

$IMNN phase 3 with 5 sites already just $12MILL!? This is a 50x right here

0 · Reply

CharlieAks Feb. 10 at 4:20 PM

$ALT $IMNN Interesting chart

1 · Reply

RaKa82 Feb. 10 at 3:26 PM

$IMNN more than half the daily average in volume this first trading hour. Interesting

0 · Reply

bomber1 Feb. 10 at 2:57 PM

$IMNN for the bullish idiots: new stock lows are being prepared!!! these few volumes with rising prices are just movements that have been going on for years... soon there will be new lows... at least 2.50 by next week

0 · Reply

stu4 Feb. 9 at 9:19 PM

$CADL …blah blah…immunology has been going on for years …this company is years behind others especially in prostate cancer , therapies exist !!! DAH ….and are working The rest of the BS here is hype , or this would be at $79 along with $KYMR , or $ARWR ….but instead is running a close 2nd behind $IMNN , hahaha

2 · Reply

RaKa82 Feb. 6 at 9:04 PM

$IMNN good day on quite a bit of volume (almost double the daily average). Don’t know what, if anything, to make of it, but I’ll take it.

0 · Reply

RaKa82 Feb. 6 at 4:16 PM

$IMNN the path here is simple. A risky investment for sure due to cash situation, but the path is simple. Generate some preliminary data, SP goes up at least 10x, which will be followed by a raise at much favorable SP, which will in turn result in at least 50x from current SP. Then it’s off to the races and sky is the limit. Lots of IFs, but the path is straightforward and I hope management can steer this thing successfully and efficiently to a quick interim readout.

1 · Reply

RaKa82 Feb. 6 at 3:55 PM

$IMNN HC Wainwright raised target to $25 (from $14)

0 · Reply

RaKa82 Feb. 6 at 3:53 PM

$IMNN https://share.google/fdQstDbEP4yjEj5BT

0 · Reply

ZacksSCR Feb. 6 at 3:23 PM

$IMNN: Streamlining Operations to Focus on OVATION 3 https://buff.ly/Le6AyMg

1 · Reply

LKDOG Feb. 5 at 10:33 PM

$IMNN 😎

1 · Reply

jjegglie Feb. 5 at 9:53 PM

$IMNN The rats are fleeing the sinking ship

0 · Reply

Market Cap	9.98M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,913
Avg Vol	53,776
Day's Range	N/A - N/A
Shares Out	3.07M
Stochastic %K	32%
Beta	2.14
Analysts	Strong Sell
Price Target	$21.50